Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 2:00 PM JST
Settings

Settings

Goto Application

1. WO2020181846 - CYSTEINE-CONTAINING ANTIBODY, DRUG CONJUGATE AND USE THEREOF

Publication Number WO/2020/181846
Publication Date 17.09.2020
International Application No. PCT/CN2019/123219
International Filing Date 05.12.2019
IPC
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 19/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
C12N 15/13 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
13Immunoglobulins
C12N 15/63 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12P 21/08 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21Preparation of peptides or proteins
08Monoclonal antibodies
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Applicants
  • 凯惠科技发展(上海)有限公司 XDCEXPLORER (SHANGHAI) CO., LTD. [CN]/[CN]
Inventors
  • 谢珍慧 XIE, Zhenhui
  • 刘礼乐 LIU, Lile
  • 张莹 ZHANG, Ying
  • 刘敬贤 LIU, Jingxian
  • 盛其然 SHENG, Qiran
  • 陈先涛 CHEN, Xiantao
Agents
  • 上海弼兴律师事务所 SHANGHAI BESHINING LAW OFFICE
Priority Data
201910181977.011.03.2019CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) CYSTEINE-CONTAINING ANTIBODY, DRUG CONJUGATE AND USE THEREOF
(FR) ANTICORPS CONTENANT DE LA CYSTÉINE, CONJUGUÉ DE MÉDICAMENT ET UTILISATION CORRESPONDANTE
(ZH) 一种含半胱氨酸的抗体、药物偶联物及其应用
Abstract
(EN)
Provided are a cysteine-containing antibody, a drug conjugate and a use thereof. The heavy chain constant region of the antibody is a humanized γ1 chain, and the light chain constant region thereof is a humanized κ chain, wherein amino acid residues at an A site of the heavy chain constant region and/or at a B site of the light chain constant region are replaced with cysteine, so as to provide an active site for site-directed coupling with drugs.
(FR)
L'invention concerne un anticorps contenant de la cystéine, un conjugué de médicament et une utilisation correspondante. La région constante à chaîne lourde de l'anticorps est une chaîne γ1 humanisée, et la région constante à chaîne légère de celui-ci est une chaîne κ humanisée, les résidus d'acides aminés au niveau d'un site A de la région constante à chaîne lourde et/ou au niveau d'un site B de la région constante à chaîne légère étant remplacés par de la cystéine, de manière à fournir un site actif pour un couplage dirigé sur site avec des médicaments.
(ZH)
提供了一种含半胱氨酸的抗体、药物偶联物及其应用。所述抗体的重链恒定区为人源γ 1链,其轻链恒定区为人源κ链,其中重链恒定区的A位点和/或轻链恒定区的B位点的氨基酸残基替换为半胱氨酸,以提供与药物进行定点偶联的活性位点。
Latest bibliographic data on file with the International Bureau